KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Merck (MRK) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Merck (MRK) over the last 17 years, with Q3 2025 value amounting to $4.1 billion.

  • Merck's Accounts Payables rose 1564.42% to $4.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 billion, marking a year-over-year increase of 1564.42%. This contributed to the annual value of $4.1 billion for FY2024, which is 400.31% up from last year.
  • As of Q3 2025, Merck's Accounts Payables stood at $4.1 billion, which was up 1564.42% from $3.9 billion recorded in Q2 2025.
  • In the past 5 years, Merck's Accounts Payables ranged from a high of $4.6 billion in Q4 2021 and a low of $3.4 billion during Q3 2021
  • For the 5-year period, Merck's Accounts Payables averaged around $3.8 billion, with its median value being $3.7 billion (2022).
  • In the last 5 years, Merck's Accounts Payables tumbled by 1064.92% in 2022 and then skyrocketed by 1564.42% in 2025.
  • Quarter analysis of 5 years shows Merck's Accounts Payables stood at $4.6 billion in 2021, then decreased by 7.49% to $4.3 billion in 2022, then fell by 8.02% to $3.9 billion in 2023, then rose by 4.0% to $4.1 billion in 2024, then rose by 1.67% to $4.1 billion in 2025.
  • Its Accounts Payables was $4.1 billion in Q3 2025, compared to $3.9 billion in Q2 2025 and $3.8 billion in Q1 2025.